As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Humacyte, Inc. The largest reported stake is Fresenius Medical Care AG's, at 9.5%. 9 filings are on record since October 16, 2025 (Schedule 13D/A, January 9, 2026).
Sell to companies like Humacyte, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fresenius Medical Care Holdings, Inc. · Sole voting: 0 · Shared voting: 13,603,235 · Sole dispositive: 0 · Shared dispositive: 13,603,235 · SCHEDULE 13D/A, 2026-08-18
- · Reporting person: BlackRock, Inc. · Sole voting: 4,092,430 · Shared voting: 0 · Sole dispositive: 4,092,430 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-28
- · Holder: Fresenius Medical Care Holdings, Inc. · Percent: 6.8% · SCHEDULE 13D/A
- · Reporting person: M.H. Davidson & Co. · Sole voting: 0 · Shared voting: 232,724 · Sole dispositive: 0 · Shared dispositive: 232,724 · SCHEDULE 13G, 2026-06-22
- · Holder: Fresenius Medical Care Holdings, Inc. · Percent: 6.8% · SCHEDULE 13D/A
Humacyte, Inc. has 9 Schedule 13D or 13G filings on record since 2025-10-16. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fresenius Medical Care AG | 9.5% | 18,312,735 | SCHEDULE 13D/A, 2026-01-09 | 2026-01-01 |
| Fresenius Medical Care Holdings, Inc. | 4.9% | 13,603,235 | SCHEDULE 13D/A, 2026-08-18 | 2026-08-14 |
| Davidson Kempner Capital Management LP | 4.74% | 12,787,073 | SCHEDULE 13G, 2026-06-22 | 2026-06-12 |
| BlackRock, Inc. | 1.5% | 4,092,430 | SCHEDULE 13G/A, 2026-07-28 | 2026-06-30 |
Holding shares or following this stake? See who's behind Humacyte, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Humacyte, Inc. and the records around it.
Humacyte, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- M.H. Davidson & Co. also filed stake reports on 17 other companies: Greenland Mines Ltd (Sep 2026), Qtrex Quantum Ltd. (Aug 2026), AIB Data Centers Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Humacyte, Inc.
Get an email when Humacyte, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Humacyte, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Humacyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Humacyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fresenius Medical Care Holdings, Inc. | 0 | 13,603,235 | 0 | 13,603,235 | SCHEDULE 13D/A, 2026-08-18 |
| Fresenius Medical Care AG | 0 | 13,603,235 | 0 | 13,603,235 | SCHEDULE 13D/A, 2026-08-18 |
| M.H. Davidson & Co. | 0 | 232,724 | 0 | 232,724 | SCHEDULE 13G, 2026-06-22 |
| Davidson Kempner Arbitrage, Equities & Relative Value LP | 0 | 12,554,349 | 0 | 12,554,349 | SCHEDULE 13G, 2026-06-22 |
| Davidson Kempner Capital Management LP | 0 | 12,787,073 | 0 | 12,787,073 | SCHEDULE 13G, 2026-06-22 |
| Anthony A. Yoseloff | 0 | 12,787,073 | 0 | 12,787,073 | SCHEDULE 13G, 2026-06-22 |
| BlackRock, Inc. | 4,092,430 | 0 | 4,092,430 | 0 | SCHEDULE 13G/A, 2026-07-28 |
The latest filing identifies Humacyte, Inc. by CUSIP 020751103 and gives its principal executive office as 2525 East North Carolina Highway 54, Durham, NC 27713 (SCHEDULE 13D/A, 2026-08-18).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-16 | Fresenius Medical Care AG | 9.9% | SCHEDULE 13D/A |
| 2026-01-09 | Fresenius Medical Care AG | 9.5% | SCHEDULE 13D/A |
| 2026-03-24 | Fresenius Medical Care Holdings, Inc. | 8.4% | SCHEDULE 13D/A |
| 2026-04-27 | Fresenius Medical Care Holdings, Inc. | 8.4% | SCHEDULE 13D/A |
| 2026-06-15 | Fresenius Medical Care Holdings, Inc. | 6.8% | SCHEDULE 13D/A |
| 2026-06-22 | Davidson Kempner Capital Management LP | 4.74% | SCHEDULE 13G |
| 2026-07-13 | Fresenius Medical Care Holdings, Inc. | 6.8% | SCHEDULE 13D/A |
| 2026-07-28 | BlackRock, Inc. | 1.5% | SCHEDULE 13G/A |
| 2026-08-18 | Fresenius Medical Care Holdings, Inc. | 4.9% | SCHEDULE 13D/A |
Questions about who owns Humacyte, Inc.
Who owns Humacyte, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Humacyte, Inc.: Fresenius Medical Care AG (9.5%, Schedule 13D/A, filed 2026-01-09).
When did Fresenius Medical Care AG buy into Humacyte, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fresenius Medical Care AG on this page is the Schedule 13D/A, filed 2025-10-16, reporting 9.9%; its latest, Schedule 13D/A filed 2026-01-09, reports 9.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Humacyte, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 28, 2026 | Leadership change: Scott Coward appointed | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Humacyte, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.